ABOUT COGNIZANT
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain. Our services and products, including the Cognizant® Shared Investigator Platform (SIP), are digitizing interactions between sponsors and investigators across every phase, helping the industry subtract time from clinical development and add it to patient lives.
Headquartered in the U.S., Cognizant is ranked 194 on the Fortune 500 and is consistently listed among the most admired companies in the world.
To learn more, visit cognizant.com/us/en/industries/life-sciences-technology-solutions
CONTACT INFORMATION
Cognizant
Glenpointe Centre West 500 Frank W Burr Blvd
Teaneck, NJ 07666
UNITED STATES
Phone: +1 201-310-2499
Contact: Kavitha Lokesh
BROCHURES
- SIP Simplifies Collaboration Between Sites And Sponsors
- Transform Clinical Trials With Cognizant SIP: Efficient, Collaborative, Virtual
- The Cognizant® Shared Investigator Platform (SIP) Document Exchange Module
- Optimize Your Safety Notification Process With The Cognizant SIP Safety Exchange Module
- Seamlessly Connect Sponsor eTMF Systems And The Florence eISF
- Cognizant® Shared Investigator Platform Video Meetings
- Modernize Operations To Support A New Way Forward For Clinical Trials With Cognizant® SIP
FEATURED ARTICLES
-
With the appropriate training data, AI has the capability to automate information gathering, document creation, and workflow management.
-
See how improvements made to SIP have allowed for quick access to study documents and bulk actions for streamlined document management and enhanced user experience.
-
Sites that lack the proper skills and staff can delay the delivery of drugs to the market. Discover how site validation can be improved by combining qualitative and quantitative data.
-
Determining the feasibility of a site for clinical research is a critical component of the entire trial process. Discover how automation and standardization can improve the site-sponsor journey.
-
Hear about the trajectory and growth of the Shared Investigator Platform, the history and impact of biomarkers in clinical trial conduct, and the personal insights from Avi Kulkarni's 30-year career.
-
Uncover how an industry pioneer and veteran biotech benefited from this solution after struggling with complexity and consistency when it came to its approach to clinical trial feasibility.
-
Cognizant SIP has maintained its growth momentum in 2021 as research sites have continued their adoption of the platform at a steady pace.
-
In the “New Normal,” Sponsors and sites collaborate remotely throughout the trial lifecycle by leveraging a solution that streamlines trial set-up and execution, leading to improved site experiences and faster time-to-market.
-
The industry needs new tools, technologies, and partnerships to collaborate virtually on clinical trials for COVID-19 treatments.
-
Why it’s time to reconsider the current drug development paradigm. Complementing traditional RCTs with accelerated RWE studies and real-time clinical analysis provides true benefits.
-
Cognizant’s Life Sciences business unit partners with biopharmaceutical and med-tech companies to develop strategies and apply solutions to healthcare challenges across the value chain.
-
Now more than ever, stakeholders need harmony among their disparate systems — and that starts with the right organizational mindset: a culture of connectivity. Here’s what our experts recommend.